OBJECTIVE: In the current posthoc analyses, we evaluated the impact of markers of aberrant data variability on drug placebo separation and placebo and drug response in an acute schizophrenia clinical trial. METHODS: Positive and negative syndrome scale data were obtained from a phase 2, randomized, double-blind, placebo controlled trial in hospitalized adults with schizophrenia experiencing an acute exacerbation. We assessed the impact of a total of six markers of aberrant data variability: erratic ratings, unusually large postbaseline improvement, high and low mean square successive difference (MSSD), identical and nearly identical ratings and compared the drug placebo difference, drug and treatment response at last visit in affected subjects vs those not affected. All analyses were conducted using generalized linear models. RESULTS: In this posthoc analysis, drug placebo separation decreased with the presence of most markers of aberrant data variability. The only exception was high MSSD was associated with significant increase in the signal. In the affected subjects, the presence of indicators of increased data variability augmented the response to placebo, in the case of large postbaseline change and high MSSD, significantly. The presence of indicators of decreased variability numerically but not statistically decreased the response to placebo. Similar findings were observed in the drug treatment group with the exception of erratic ratings that numerically but not statistically decreased the response to the drug. DISCUSSION: The presence of most indicators of aberrant data variability had a detrimental effect on drug-placebo separation and showed different effects on placebo and treatment response.

Karuna Therapeutics Boston MA USA

Signant Health Blue Bell PA USA

Signant Health Mclean VA USA

Signant Health Prague Czech Republic

See more in PubMed

Hjorthøj C, Stürup AE, McGrath JJ, Nordentoft M. Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. Lancet Psychiatry. 2017;4(4):295–301. PubMed

Vos T, Barber RM, Bell B, et al. . Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386(9995):743–800. PubMed PMC

Leucht S, Leucht C, Huhn M, et al. . Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors. Am J Psychiatry. 2017;174(10):927–942. PubMed

Kinon BJ, Zhang L, Millen BA, et al. ; HBBI Study Group . A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia. J Clin Psychopharmacol. 2011;31(3):349–355. PubMed

Alphs L, Benedetti F, Fleischhacker WW, Kane JM. Placebo-related effects in clinical trials in schizophrenia: what is driving this phenomenon and what can be done to minimize it? Int J Neuropsychopharmacol. 2012;15(7):1003–1014. PubMed PMC

Leucht S, Chaimani A, Mavridis D, et al. . Disconnection of drug-response and placebo-response in acute-phase antipsychotic drug trials on schizophrenia? Meta-regression analysis. Neuropsychopharmacology. 2019;44(11):1955–1966. PubMed PMC

Umbricht D, Kott A, Daniel DG. The effects of erratic ratings on placebo response and signal detection in the Roche bitopertin phase 3 negative symptom studies—a post hoc analysis. Schizophr Bull Open. 2020;1(1):203.

Jahng S, Wood PK, Trull TJ. Analysis of affective instability in ecological momentary assessment: Indices using successive difference and group comparison via multilevel modeling. Psychol Methods. 2008;13(4):354–375. PubMed

Hermes ED, Sokoloff D, Stroup TS, Rosenheck RA. Minimum clinically important difference in the Positive and Negative Syndrome Scale with data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). J Clin Psychiatry. 2012;73(4):526–532. PubMed PMC

Kott A, Brannan SK, Wang X, Murphy C, Targum SD, Daniel DG. Procedures to optimize endpoint data quality in an acute schizophrenia study. Poster presentation at the ISCTM 2020 Autumn Virtual Conference, September 21–25, 2020.

Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–276. PubMed

Kott A, Daniel DG. Rater change associated with identical scoring of the PANSS as a marker of poor data quality. Poster presentation at the 2014 CNS Summit held in Boca Raton, Florida, 13–16 November 2014.

The Impact of Baseline Anxiety on Drug Placebo Separation and Drug/Placebo Response in an Acute Schizophrenia Clinical Trial-A Post-hoc Analysis